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Abstract
Atherosclerosis is currently understood to be mainly the consequence of a complicated 
inflammatory process at the different stages of plaque development. Among the several 
inflammatory molecules involved, up-regulation of the functional cyclooxygenase 2/membrane-
bound prostaglandin E synthase 1 (COX-2/mPGES-1) axis plays a key role in plaque development. 
Excessive production of oxidized lipids, following low-density lipoprotein (LDL) oxidation, is a 
characteristic feature of atherosclerosis. Among LDLs, the oxysterol 27-hydroxycholesterol (27-
OH) and the aldehyde 4-hydroxynonenal (HNE) substantially accumulate in the atherosclerotic 
plaque, contributing to its progression and instability through a variety of processes. This study 
shows that 27-OH and HNE promote up-regulation of both the inducible enzymes COX-2 and 
mPGES-1, leading to increased production of prostaglandin (PG) E2 and inducible nitric oxide 
synthase, and the subsequent release of nitric oxide in human promonocytic U937 cells. The study 
also examined the potential involvement of the functionally coupled COX-2/mPGES-1 in 
enhancing the production of certain pro-inflammatory cytokines and of matrix metalloproteinase 9 
by U937 cells. This enhancement is presumably due to the induction of PGE2 synthesis, as a result 
of the up-regulation of the COX-2/mPGES-1, stimulated by the two oxidized lipids, 27-OH and 
HNE. Induction of PGE2 synthesis might thus be a mechanism of plaque instability and eventual 
rupture, contributing to matrix metalloproteinase production by activated macrophages. 
Keywords: Atherosclerosis; Inflammation, Plaque instability; 27-Hydroxycholesterol; 4-
Hydroxynonenal. 
Abbreviations: 27-OH, 27-hydroxycholesterol; COX-2, cyclooxygenase-2; EC, endothelial cell; 
EGCG, epigallocatechin gallate; ERK, extracellular signal-regulated kinases; HNE, 4-
hydroxynonenal; IL, interleukin; iNOS, inducible nitric oxide synthase; LDL, low density 
lipoprotein; LXR, liver X receptor; MMP, matrix metalloproteinase; mPGES-1, membrane-bound 
prostaglandin E synthase-1; NF-B, nuclear factor-B; NO, nitric oxide; oxLDL, oxidized LDL; 
PG, prostaglandin; PK, protein kinase; ROS, reactive oxygen species; SMC, smooth muscle cell; 
TIMP, tissue inhibitor of MMP; TLR4, Toll-like receptor 4; TNF-, tumor necrosis factor. 
1. Introduction
Atherosclerosis is a complex chronic inflammatory disease of the vessel wall. Inflammation, 
as well as innate and adaptive immune responses, and oxidative stress play a central role in all 
stages of atherosclerosis including the transition of stable atherosclerotic plaques to unstable 
plaques [1,2]. 
Development of atherosclerotic lesions is preceded by impaired vascular endothelium 
function which favors the retention and accumulation of low-density lipoproteins (LDLs) in the 
sub-endothelial space by specific proteins of extracellular matrix, including collagen and 
proteoglycan.  Here, the lipid moieties of LDL undergo lipid peroxidation resulting in the release of 
various reactive oxidized lipids, including aldehydes, cholesterol oxidation products, and oxidized 
phospholipids. Many studies have demonstrated that accumulation of plaque lipids enhances plaque 
formation, supporting the concept that the plaque is atherogenic. Oxidized LDLs (oxLDLs), which 
accumulate progressively in atherosclerotic lesions, stimulate smooth muscle cell (SMC) 
differentiation and proliferation, monocyte/macrophage recruitment and differentiation, platelet 
aggregation, up-regulation of leukocyte adhesion molecules, and matrix metalloproteinase (MMP) 
activation. Finally, the intercellular cross-talk that occurs among vascular cells leads to a 
fibroproliferative response. During this response, the extracellular matrix components, released by 
differentiated SMCs, play a key role in plaque formation and progression, providing the structural 
integrity of the plaque itself, as well as contributing to cell migration and proliferation [1]. 
In particular, the interaction between oxLDLs and monocyte/macrophage plays predominant 
roles during initiation and progression of atherosclerosis. Activated macrophages not only take up 
the oxLDLs through the scavenger receptor CD36 to form lipid-loaded foam cells, but also release 
pro-inflammatory molecules, such as cytokines, chemokines, and adhesion molecules [1]; the 
release of inflammatory molecules induces an inflammatory state, with subsequent activation of the 
other arterial wall cells, resulting in a lesion that is unstable and prone to rupture when exposed to 
increasing hemodynamic stress. Plaques vulnerable to rupture - the major cause of acute coronary 
syndrome - are characterized by a lipid-rich necrotic core, accumulation of inflammatory cells, and 
fibrous cap weakening, due both to ongoing inflammation and to an imbalance between 
extracellular matrix synthesis and degradation [3-6].
Of the inflammatory molecules involved, cyclooxygenase 2 (COX-2), which is an inducible 
enzyme and overexpressed by activated macrophages in atherosclerotic plaques, may participate in 
the pathogenesis of plaque progression and instability through a variety of processes. These 
comprise activation of chemotaxis, induction of vascular permeability, propagation of inflammatory 
molecules, stimulation of SMC migration, and the resultant induction of itself. Thus COX-2 is 
responsible for the production of eicosanoids, mainly prostaglandin (PG) E2, in inflammatory 
diseases. PGE2 is formed from arachidonic acid via the COX-2-catalyzed formation of PGH2 and 
further transformation by PGE synthases. The isomerization of the endoperoxide PGH2 to PGE2 is 
catalyzed by three different PGH synthases: a cytosolic PGE synthase (cPGES), and two 
membrane-bound PGE synthases (mPGES-1 and mPGES-2). mPGES-1 is mainly an induced 
isomerase, and uses COX-2-derived endoperoxide; it is therefore up-regulated in response to 
various pro-inflammatory stimuli, with a concomitant increased expression of COX-2 [7-9].
Expression of inducible nitric oxide synthase (iNOS) also occurs in conditions of inflammation, and 
produces a large amount of nitric oxide (NO), which contributes to the up-regulation of COX-2 and 
to the subsequent release of PGE2 upon direct interaction with the COX-2 enzyme. A crucial link 
between iNOS and COX-2 pathway has thus been suggested [10-12].
Much evidence deriving from in vitro and ex vivo studies has implicated MMPs, mainly 
MMP-2 and MMP-9, in plaque instability and rupture, because of their ability to degrade all 
macromolecular constituents of the extracellular matrix [13-17]. Induction of expression and 
activity of MMP-2 and MMP-9 by activated macrophages has been shown to occur through a 
PGE2/cAMP-dependent pathway, involving the simultaneous up-regulation of COX-2 and mPGES-
1 [15,18]. It has been shown that these two enzymes, COX-2 and mPGES-1, are simultaneously up-
regulated by pro-inflammatory stimuli, such as the release of growth factors and cytokines [19]. 
The enhanced production of MMPs in vulnerable regions of unstable atherosclerotic plaques 
may, thus, be due to the increased release of PGE2, due in turn to induction of the functionally 
COX-2/mPGES-1 axis by inflammatory stimuli. In addition to increased biosynthesis of PGE2-
dependent MMPs in the atherosclerotic plaque setting, PGE2 can also amplify the release of 
cytokines, and inflammatory cytokines can directly enhance the synthesis of MMPs in activated 
macrophages [20,21]. Clearly, all these events play critical roles in enhancing and sustaining a 
vicious circle that might result in plaque rupture. Of note, among the MMPs, MMP-9 has been 
consistently implicated in plaque instability and rupture [22]. Various inflammatory molecules, in 
particular PGE2 and cytokines, as well as oxidative stress molecules such as reactive oxygen species 
(ROS), play crucial roles in the cross-talk among vascular cells leading to up-regulation of MMPs 
[23,24].  
It has been extensively demonstrated that lipids carried by oxLDLs activate monocytes and 
macrophages during atherosclerotic inflammatory processes, and that they contribute to increasing 
and sustaining pro-inflammatory molecule production [25-27].
Among the oxidized plaque lipids, the oxysterol 27-hydroxycholesterol (27-OH), a 
cholesterol oxidation product, and the aldehyde 4-hydroxynonenal (HNE), one of the more reactive 
end products of polyunsaturated fatty acid (PUFA) peroxidation, play key roles in the pathogenesis 
of atherosclerosis. They act by stimulating various signal transduction pathways that are involved 
both in the inflammatory response and in the immune response and oxidative stress [28-31]. 
Based on these considerations, it was decided to investigate whether the oxysterol 27-OH 
and the aldehyde HNE, which substantially accumulate in the atherosclerotic plaque, may up-
regulate COX-2 and mPGES-1, resulting in the induction of PGE2 synthesis; this might be a 
mechanism of plaque instability and eventual rupture, contributing to the production of 
inflammatory cytokines and MMPs by activated macrophages. The study found an enhanced 
production of certain pro-inflammatory cytokines and of MMP-9, presumably due to the induction 
of PGE2 synthesis, as a result of the up-regulation of the functionally coupled inducible COX-
2/mPGES-1, in human promonocytic U937 cells stimulated by the oxidized lipids 27-OH and HNE.
2. Methods
2.1. Cell culture and treatments
The human promonocytic cell line U937 was cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (Invitrogen, Life Technologies, Monza, Italy), 100 U/mL penicillin, 
100 μg/mL streptomycin, and 2 mM glutamine (Sigma-Aldrich, Milan, Italy) at 37 °C with 5% 
CO2. The cells were dispensed at 1x106/ml and made quiescent through overnight incubation in 
serum-free medium. They were then placed in RPMI 1640 medium with 2% fetal bovine serum and 
treated with 6 μM 27-OH (Avanti Polarlipids, Alabaster, AL, USA) or in serum-free RPMI 1640 
medium and treated with 5 μM HNE (Alexis, Vinci-Biochem, Vinci, Italy). In certain experiments, 
cells were pretreated for 1 h with 25 μM of NS-398, a specific inhibitor of COX-2 or with 10 μM 
epigallocatechin gallate (EGCG) (Sigma-Aldrich). Final concentrations and incubation times for all 
experiments are given in the figure legends.
2.2. RNA extraction
Total RNA was extracted from cells using TRIzol reagent (Applied Biosystems, Thermo 
Fisher Scientific, Monza, Italy), following the manufacturer's instructions, after treatment with 27-
OH or HNE. RNA was dissolved in RNase-free water with RNase inhibitors (RNase SUPERase-In; 
Applied Biosystems, Thermo Fisher Scientific). The amount and purity (A260/A280 ratio) of the 
extracted RNA were assessed spectrophotometrically.
2.3. cDNA preparation and real-time RT-PCR
cDNA was synthesized by reverse transcription from 2 μg RNA with a commercial kit and 
random primers (High-Capacity cDNA reverse transcription kit; Applied Biosystems, Thermo 
Fisher Scientific), following the manufacturer's instructions. Singleplex real-time RT-PCR was 
performed on 40 ng of cDNA using TaqMan gene expression assay kits prepared for human 
mPGES-1, iNOS, interleukin-8 (IL-8), IL-1, tumor necrosis factor- (TNF-), MMP-9, and -
actin and TaqMan Fast Universal PCR master mix, and analyzed by a 7500 Fast real-time PCR 
system (Applied Biosystems, Thermo Fisher Scientific). The oligonucleotide sequences are not 
revealed by the manufacturer because of proprietary interests. The cycling parameters were as 
follows: 20 s at 95 °C for AmpErase UNG activation, 3 s at 95 °C for AmpliTaq Gold DNA 
polymerase activation, and 40 cycles of 3 s each at 95 °C (melting) and 30 s at 60 °C 
(annealing/extension). The fractional cycle number at which fluorescence passes the threshold in 
the amplification plot of fluorescence signal versus cycle number was determined for each gene 
considered. The results were then normalized to the expression of -actin, as housekeeping gene. 
Target gene expression was quantified relatively with a mathematical method proposed by Livak 
and Schmittgen [32].
2.4. Analysis of mPGES-1, IL-8, IL-1, and TNF- by immunofluorescence, and detection by 
confocal laser microscopy 
After treatments, cells were transferred onto glass slides (8x104 cells/slide) by 
cytocentrifugation. Specimens were fixed in cold methanol for 10 min and permeabilized for 10 
min with 0.1 M PBS-0.4% Triton X-100 solution. Cells were then incubated with a 100 mM sodium 
cyanoborohydride reducing agent for 10 min at 37 °C. After blocking nonspecific sites of binding 
with 0.1 M PBS containing 5% goat serum, 3% BSA, and 0.3% Tween 20, slides were incubated in 
the presence of primary antibodies against mPGES-1 (1:200), IL-8 (1:100), IL-1 (1:50), and TNF-
 (1:50) (Santa Cruz Biotechnology, Dallas, TX, USA) and then with specific secondary antibodies 
(1:200) conjugated with fluorescein isothiocyanate (FITC) or tetramethylrhodamine isothiocyanate 
(TRITC) fluorochromes (Alexa Fluor, Molecular Probes, Thermo Fischer Scientific). Slides 
mounted with glycerol and distilled water (1:1) were observed through an LSM 510 confocal laser 
microscope (Carl Zeiss SpA, Arese, Milan, Italy) equipped with an inverted microscope with Plan-
NEOFLUAR lenses (40 x/0.75).
2.5. Analysis of COX-2 by Western blotting
Cells were lysed in ice-cold buffer containing 20 mM Hepes, pH 7.9, 0.35M NaCl, 20% 
glycerol, 1% Igepal CA-630, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, and protease inhibitors 
and centrifuged at 14000 rpm for 15 min. For COX-2 protein, 50 μg of total proteins were boiled 
for 5 min in Laemmli buffer and separated in 10% denaturing SDS/polyacrylamide gels followed by 
transfer to nitrocellulose membranes. Filters were blocked with 5% nonfat dried milk in Tris-
buffered saline (TBS) 1X-0.05% Tween 20 for 1 h at room temperature and incubated overnight at 
4 °C with the appropriate primary antibody against COX-2 (1:250) diluted in 5% nonfat dried milk 
or in 1% bovine serum albumin in TBS 1X-0.05% Tween 20, followed by specific horseradish 
peroxidase (HRP)-conjugated secondary antibody for 2 h at room temperature (Santa Cruz 
Biotechnology). The membranes were then stripped with the Restore Western blot stripping buffer 
(Pierce Biotechnology, Rockford, IL, USA) and again immunoblotted with anti-actin primary 
antibody (1:6000) (Sigma-Aldrich) and then incubated with a specific secondary antibody, as 
described above. Proteins were detected using the Clarity Western ECL subtrate (Bio-Rad 
Laboratoires, Segrate, Milan, Italy) following the manufacturer's protocol. The immunoreactive 
bands were scanned and subjected to densitometric analysis using the Image Tool software package. 
The results are expressed in relative units, determined by normalizing the density of each band of 
the corresponding reference protein band.
2.6. NO measurement by Griess reaction
NO concentration was determined by quantifying the stable end-product of NO, i.e. nitrite. 
A colorimetric assay kit (Griess Reagent Kit for Nitrite Determination) based on the Griess reaction 
was used following the manufacturer’s instructions (Molecular Probes, Thermo Fisher Scientific). 
Briefly, 80 µl of supernatant collected after 48 h cell treatment were sequentially mixed with 80 µl 
of a 1% solution of sulfanilic acid in 5% phosphoric acid and 80 µl of a 0.1% solution of N-(1-
naphthyl) ethylenediamine dihydrochloride. The mixture was kept at room temperature for 30 min. 
The absorbance was measured at 550 nm in a microplate reader. Nitrite concentrations were 
calculated from a standard curve obtained by diluting the sodium nitrite stock solution contained in 
the kit in cell medium.
2.7. PGE2 determination by enzyme immunoassay (EIA)
After U937 cell treatment with 6 M 27-OH or 5 M HNE for 24 h, supernatants were 
collected, centrifuged, and stored at -80 °C. Supernatants were purified using a C-18 column, as per 
the manufacturer’s protocol. After evaporation of ethyl acetate under nitrogen stream, and 
resuspension of sample in EIA buffer, levels of PGE2 were measured using a commercially-
available enzyme immunoassay kit (Prostaglandin E2 ELISA Kit-monoclonal) following the 
manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI, USA). Absorbance was measured 
at 415 nm in a microplate reader. 
2.8. Evaluation of MMP-9 protein levels by enzyme linked immunosorbent assay (ELISA)
After treatments, cells were lysed and cytosolic proteins were stored for ELISA detection. 
MMP-9 levels were quantified using the DuoSet ELISA kit (R&D System, MN, USA), following 
the manufacturer's instructions. The plates were read at 450 nm with wavelength correction of 550 
nm in a microplate reader (Model 680 Microplate Reader, Bio-Rad). The concentrations of MMP-9 
were extrapolated from the standard curve.
2.9. Statistical analysis
All values are expressed as means ± standard deviation (SD). Statistical analysis of the data 
was by one-way ANOVA with Bonferroni's post-test for multiple comparisons. Differences with p< 
0.05 were considered statistically significant. Statistical calculations were done with the GraphPad 
InStat3 software package (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. The lipid oxidation products 27-OH and HNE up-regulate both COX-2 and mPGES-1 in U937 
cells
To investigate whether 27-OH and HNE are involved in the simultaneous up-regulation of 
COX-2 and mPGES-1, human promonocytic U937 cells were incubated with these two oxidized 
lipids. The oxysterol 27-OH was used at 6 M, a concentration mimicking the amount found in 
atherosclerotic plaques [33], while the aldehyde HNE was used at a concentration of 5 M, which is 
below that found in inflamed and diseased tissues [34].
The effects of 27-OH and HNE on the protein levels of COX-2 were analyzed by Western 
blotting, while the expression and synthesis of m-PGES-1 were quantified by real-time RT-PCR 
and confocal laser microscopy, respectively. 
Both oxidized lipids significantly induced COX-2 protein levels after 24 h cell treatment 
(Fig. 1 A), compared to untreated cells (control). Further, an approximately time-dependent increase 
of mPGES-1 mRNA levels was observed from 2 to 6 h of treatment, compared with untreated cells 
(control), in particular after cell treatment with HNE (5 M). However, both oxidized lipids 
significantly induced mPGES-1 expression after 6 h cell treatment (Fig. 1B). An increase of 
mPGSE-1 protein levels was observed by immunofluorescence analysis, using a confocal laser 
microscope, after 24 h cell incubation with either 27-OH or HNE (Fig. 1C).
3.2. Induction of PGE2 production by U937 cells treated with 27-OH or HNE
COX-2 and mPGES-1, induced in response to inflammatory stimuli, are involved in 
prostaglandin generation in inflammatory diseases, including atherosclerosis [7,9]. Among 
prostaglandins, PGE2 plays a key role in the setting of human atherogenesis.
The effects of 27-OH (6 M) and HNE (5 M) on PGE2 production by human promonocytic 
U937 cells was checked by ELISA after 24 h treatment. PGE2 production, as a result of induction of 
the functional COX-2/mPGES-1 axis, was consistently induced by both compounds compared to 
untreated cells (control) (Fig. 2). As noticed in previous results concerning COX-2/mPGES-1 up-
regulation, again in this case the strongest effect on PGE2 production occurred in cells treated with 
HNE. 
3.3. Both 27-OH and HNE up-regulate iNOS and NO
Expression of iNOS occurs in condition of inflammation, and its activation promotes and 
maintains the production of NO. Cross-communication between iNOS and COX-2 has been 
suggested, since NO contributes to the up-regulation of COX-2 and the subsequent release of PGE2; 
these play crucial roles in plaque instability. 
To investigate whether 27-OH or HNE stimulate iNOS expression, U937 cells were 
incubated with 6 M 27-OH or 5 M HNE for up to 6 h. A time-dependent increase of iNOS 
mRNA levels was observed from 2 to 6 h of cell treatment with HNE compared with untreated cells 
(control), while in cells incubated with 27-OH a significant increase of iNOS expression occured 
only after 6 h treatment (Fig. 3A).  As a consequence of the increased expression of iNOS, an 
increased production of NO (in terms of nitrite) was then observed using the colorimetric assay kit, 
in cells treated for 48 h with either compound (Fig. 3B).
3.4. Down-regulation of mPGES-1 by the anti-inflammatory effect exerted by EGCG in U937 cells 
treated with 27-OH or HNE 
The pathophysiological role of the functional COX-2/mPGES-1 axis also depends on the 
induction of mPGES-1 expression by pro-inflammatory stimuli [35,36]. 
To determine whether natural compounds, such as polyphenols, may act as anti-
inflammatory molecules, cells were pretreated with the flavanol EGCG (10 M). A significant 
reduction in mPGES-1 expression was observed in the presence of EGCG after 6 h cell incubation 
with 27-OH (6 M) or HNE (5 M), compared with cells treated with 27-OH or HNE alone (Fig. 
4). EGCG may act by preventing the inflammatory state that is generated in U937 cells upon 
incubation with the oxysterol or the aldehyde; this would reduce the expression of COX-2 and 
mPGES-1, critical enzymes in the progression of atherosclerotic plaque, and in the formation of 
functionally-coupled COX-2/mPGES-1. 
3.5. Up-regulation of IL-8, IL-1 and TNF- by 27-OH and HNE: implication of functionally-
coupled COX-2/mPGES-1 in cytokine release 
The enhanced PGE2 synthesis as a consequence of COX-2/mPGES-1 induction may amplify 
the release of inflammatory cytokines by activated macrophages. Both PGE2 and inflammatory 
cytokine release contribute to atherosclerotic plaque instability, by increasing MMP production with 
consequent matrix break-down [37,38].
Among the inflammatory cytokines involved in the pathogenesis of atherosclerosis, the 
effect of 6 M 27-OH and of 5 M HNE on IL-8, IL-1, and TNF- expression and synthesis on 
U937 cells was determined by real-time RT-PCR, or by immunofluorescence analysis using a 
confocal laser microscope, respectively.
Expression of all the cytokines considered was significantly increased by 27-OH and HNE 
after 6 h treatment, compared with untreated cells (Fig. 5A). Increased protein levels of these 
inflammatory cytokines were also clearly detected by confocal microscopy after 24 h cell treatment 
(Fig. 5B).
To investigate involvement of the COX-2 pathway and of inflammatory stimuli on IL-8, IL-
1, and TNF- release by U937 cells incubated with 27-OH (6 M) or HNE (5 M), the cells were 
pretreated with 25 M NS-398, a selective inhibitor of COX-2, or with 10 M EGCG, an anti-
inflammatory molecule. Expression (Fig. 5A) and protein levels (Fig. 5B) of all the cytokines 
examined were markedly decreased, supporting the involvement of COX-2/mPGES-1 and of the 
subsequent PGE2 production, in exacerbating the inflammatory state that contributes to plaque 
instability.
3.6. Involvement of COX-2 pathway on up-regulation of MMP-9 by 27-OH and HNE in U937 cells 
The protease MMP-9 plays a fundamental role in the instability and eventual rupture of 
atherosclerotic plaques [20-22]. Its expression and proteolytic activity can be up-regulated by 
different cell signaling pathways, which may be interconnected. Among them, several studies point 
to MMP-9 release occurring through a COX-2/mPGES-1/PGE2 pathway [18,39,40]. 
The effects of 27-OH (6 M) and HNE (5 M) on MMP-9 expression and synthesis were 
thus explored, by real-time RT-PCR after 24 h treatment, and by ELISA after 48 h treatment, 
respectively. Of note, the ELISA kit employed recognizes both inactive and active forms of MMP-
9. In human promonocytic U937 cells, MMP-9 expression (Fig. 6A) and protein levels (Fig. 6B) 
were consistently induced both by the oxysterol and by the lipid aldehyde, compared with untreated 
cells (control).
To investigate whether the production of MMP-9 by U937 cells occurs through a COX-2-
dependent pathway, cells were pretreated with NS-398 (25 M) or with EGCG (10 M). With the 
specific COX-2 inhibitor or the natural anti-inflammatory flavanol, the up-regulation of MMP-9 
expression and synthesis induced by 27-OH or HNE was significantly decreased compared with 
control cells (Fig. 6A,B).
These data support the potential role of COX-2/mPGES-1 and, presumably, of PGE2 in MMP-9 up-
regulation, in enhancing plaque instability.
4. Discussion 
Current understanding of the pathogenesis of atherosclerosis suggests the involvement of 
complex mechanisms that go beyond the mere storage of oxLDLs: it is now clear that inflammation 
plays a critical role in the cascade of events that lead to atherosclerotic plaque rupture [1,3,4]. 
OxLDLs can stimulate inflammatory activation of vascular cells acting as “danger associated 
molecular patterns” (DAMPs). They also provide oxidation-specific epitopes that are recognized by 
innate natural immunoglobulin M (IgM) antibodies, as well as by C-reactive protein and 
complement protein system. Although the natural IgM antibodies can facilitate the clearance of 
oxLDLs, the overstimulation of the innate immune system can lead to the development of an 
autoimmune response that includes both immunoglobulin class switching (e.g. to IgG), affinity 
maturation of antibodies, and the release of T-lymphocyte response to oxLDLs. All these events can 
contribute to maintain inflammation and the progression of atherosclerotic lesions [41]. In this 
connection, while the IgM anti-oxLDLs are able to reduce the atherosclerotic events, in turn the IgG 
antibodies stimulate the secretion of pro-inflammatory cytokines contributing to oxLDL 
accumulation at sub-endothelial sites and atherosclerotic plaque formation [42]. 
As part of the inflammatory response within atheroma, both the inducible enzymes, COX-2 
and mPGES-1, are simultaneously up-regulated in activated macrophages, by inflammatory stimuli 
including cytokines; this leads to the subsequent production of eicosanoids, mainly PGE2 which 
participate in the pathogenesis of atherosclerotic plaque formation and instability through a variety 
of processes [7,19,43-45].
Both pharmacologic and direct genetic evidence implicate COX-2 over-expression in 
atherosclerotic lesion formation [21,46,47]. COX-2 has been detected in the fatty streaks of both 
humans and mice, and its pro-atherogenic role has been demonstrated using rofecoxib, a highly 
selective COX-2 inhibitor, which reduced the formation of fatty streaks in the vascular wall [46,48]. 
COX-2 is also extensively expressed, alongside mPGES-1, by activated macrophages within 
advanced human atherosclerotic plaques, and to a lesser extent by SMCs and ECs, whereas low or 
even undetectable levels of COX-2 are found in normal human arteries. Of note, macrophages of 
the shoulder region contain most of the COX-2 protein level within the atherosclerotic lesion 
[15,44]. However, it has been observed that macrophage foam cells of atherosclerotic plaques do 
not express COX-2, thus suggesting that the enzyme is down-regulated in mature foam cells 
[15,46].  Interestingly, it has also been shown that mice lacking COX-2, mice expressing modified 
COX-2, and mice treated with a COX-2 inhibitor, all produce significantly less prostacyclin than 
normal animals whereas thromboxane formation remains unaltered, and the animals develop 
thrombosis and hypertension [49]. Moreover, in mPGES-1 knockout mice, a 30% reduction in 
macrophage foam cells was observed in the atherosclerotic plaques, which also displayed less 
necrosis [50]. 
The enzyme iNOS is also induced by inflammatory stimuli, such as cytokines, and it 
potentially regulates the development of atherosclerosis, thanks to its ability to produce 
peroxynitrite (ONOO-), which contributes to endothelial dysfunction [51], and to produce excess 
NO [11]. The involvement of iNOS up-regulation in the pathogenesis of atherosclerosis is 
supported by the observation, in apolipoprotein E-deficient mice, that genetic iNOS deficiency 
reduced diet-induced atherosclerotic lesion formation [52]. Nanomolar amounts of NO are 
continuously generated by iNOS, which is regulated by many cell types, including macrophages, 
neutrophils, ECs and SMCs. Excess NO can impair cholesterol efflux in macrophage foam cells, 
suggesting that iNOS may reduce plaque healing [53], but it can also contribute to COX-2 up-
regulation, supporting cross-talk among the iNOS/NO/COX-2 pathways, leading to an increased 
release of PGE2 as a consequence of direct interaction with the COX-2 enzyme [11,12]. The 
relationship between iNOS and COX-2 is also supported by the co-localization of iNOS and COX-
2, predominantly in macrophages/foam cells, in both native and transplanted human coronary 
arteries [54]. The enhancing effects of pro-inflammatory cytokines on iNOS and NO expression has 
been demonstrated by inhibiting iNOS and COX-2 induction, using anti-inflammatory steroids that, 
in parallel, reduced both NO and PGE2 generation [55,56], as well as by employing the selective 
iNOS inhibitor aminoguanidine [57]. 
It has also been shown that oxLDLs induce COX-2 expression by extracellular signal-
regulated kinase (ERK) activation, and that COX-2 is expressed in atherosclerotic lesions, where it 
promotes inflammation [15,58]. Increased COX-2 expression was found in LDL receptor-/- mice, in 
which it contributed to atherogenesis [46]. Oxysterols and aldehydes play a crucial role among 
lipids carried by oxLDLs that activate macrophages, contributing and sustaining inflammation 
during atherosclerotic plaque progression. Of note, it has been demonstrated that accumulation in 
the vessel walls of foam cell-derived HNE might promote vascular EC senescence [59]. Moreover, 
HNE accumulate in an age-related manner in the arterial walls contributing to elastin degradation 
thus favoring the development of the atherosclerotic lesions [60]. However, in a recent study, it has 
been reported that low levels of the aldehydes HNE and 4-hydroxy-2E-,6Z-dodecadienal (4-HDDE) 
induce an hormetic response which counteract stressful stimuli allowing vascular endothelial cells 
to restore their normal functions [61]. 
The present study demonstrated that 27-OH, the most abundant circulating oxysterol, and 
HNE, the most reactive aldehyde, both of which accumulate markedly in atherosclerotic plaques, 
are able to increase COX-2 (Fig. 1A) and mPGES-1 (Fig. 1B and C) levels, resulting in the 
induction of PGE2 release (Fig. 3) in human promonocytic U937 cells. In U937 cells, increased 
iNOS expression (Fig. 2A) and NO levels (Fig. 2B) were also observed after cell treatment with 27-
OH or with HNE. The data indicate that oxidized lipids may stimulate these inducible enzymes, 
thus triggering release of their products which contribute to inflammation and plaque instability.
During inflammation, abundant pro-inflammatory cytokines are produced by macrophages, 
following activation of several mechanisms, including up-regulation of COX-2/mPGES-1. In turn, 
cytokines are themselves responsible for both COX-2 and mPGES-1 up-regulation. In particular, it 
has been shown that interferon- (IFN-) in combination with TNF- induces a synergistic increase 
of COX-2 mRNA in human macrophages [19]. Moreover, a mixture of IL-1, TNF-, and IFN- 
enhances the release of PGE2 and COX-2 activity in human pulmonary epithelial cells [62]. IL-1 is 
also a potent inducer of COX-2 expression in various cell types, including osteoblasts [63], while 
stimulation of human microglia with IL-8 effectively increases expression of pro-inflammatory 
cytokines and COX-2 [64]. The expression of mPGES-1 is also markedly increased in various cells 
and tissues by the same pro-inflammatory stimuli (i.e. IL-1, TNF-) involved in COX-2 induction 
[65].
In this connection, it was observed that cell pretreatment with the flavanol EGCG, a 
polyphenol with anti-inflammatory and antioxidant properties, significantly decreased the 
expression of mPGES-1 induced by 27-OH or HNE (Fig. 4). The release of certain cytokines, 
mainly involved in atherosclerotic plaque instability, which is induced by these oxidized lipids, 
markedly decreased in cells preincubated with NS-398, a specific inhibitor of COX-2, or with 
EGCG (Fig. 5). 
Of note, the simultaneous up-regulation of functionally-coupled COX-2/mPGES-1, during 
the inflammatory response in macrophages, may also be due to PGE2 itself, via a positive-feedback 
regulation of both the PGE2-synthesizing enzymes. PGE2 is able to induce transcriptional activation 
of the two enzymes, by over-expressing its receptor EP2, with consequent activation of the 
cAMP/protein kinase A/cAMP-response element-binding protein (cAMP/PKA/CREB) signaling 
pathway [66]. 
With regard to atherosclerotic plaque instability, increased expression and activity of MMPs, 
in particular of MMP-2 and MMP-9, has been observed in unstable human carotid plaques, in 
association with macrophages [13,67]. The increase of MMPs in advanced atherosclerotic plaques 
has the potential to cause acute plaque rupture and the subsequent thrombotic events. Expression 
and proteolytic activities of MMPs are induced by several stimuli or mediators, through activation 
of various interconnected signaling pathways [16,17].
Several cytokines, chemokines, and growth factors regulate MMP expression at the 
transcriptional level, and also regulate their cell release [23,24]. For example, it has been reported 
that IL-1 and IL-8 can release a local imbalance between MMPs and tissue inhibitor of MMPs 
(TIMPs) by inhibiting TIMP-1 expression in macrophages [68,69]. In this connection, in human 
promonocytic U937 cells, it has been demonstrated that the oxysterol 27-OH and the reactive 
aldehyde HNE may promote plaque instability through activation of Toll like receptor 4/nuclear 
factor-κB (TLR4/NF-κB) pathway, which seems to up-regulate MMP-9 by increasing local 
inflammatory cytokine release, or even directly [17]. 27-OH also contributes to inflammation by 
enhancing the production of IL-8 in macrophages through activation of NF-B [70] as well as 
monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1), 
and MMP-9 in THP-1 cells [71]. To confirm that an inflammatory state can contribute to MMP-9 
expression, specific antibodies were used to block the action of IL-8, IL-1, and TNF-, which are 
released following cell treatment with 27-OH or HNE and TLR4/NF-κB pathway activation; both 
MMP-9 mRNA and protein levels were consistently decreased, confirming the importance of these 
cytokines in regulating the protease levels induced by both the oxidized lipids [17]. 
Although 27-OH has been studied for its involvement in pro-inflammatory processes, it is 
now well known that it plays also a role as ligand for liver X receptors (LXRs), transcription factors 
that regulate an array of genes, including genes involved in anti-inflammatory response [72]. The 
dual effect of 27-OH on inflammatory process depends on the fact that it is a weak LXR agonist and 
that 27-OH can bind signaling molecules different from LXRs, thus inducing expression of 
inflammatory markers. Several studies on LXR ligands, deriving from the use of synthetic agonists 
of LXR which fully activate it, demonstrated anti-inflammatory effects of LXR [73]. In this 
connection, treatment with LXR agonists (e.g. T0901317) reduces atherosclerosis in vivo through 
inhibition of various inflammatory gene expression, including TNF-, IL-1, IL-6, COX-2, iNOS, 
and NF-B [74]. Of note, LXR activation induces the expression of genes different from those 
stimulated by endogenous oxysterols. Therefore, although LXR-activating oxysterols might reduce 
inflammation, they can also act by activating opposing pathways and inducing expression of 
inflammation markers independently of LXRs [73]. Another beneficial effect of 27-OH is due to its 
ability to protect human macrophages from cholesterol overload [75] since oxysterols, by binding to 
LXR, might act as “cholesterol sensors”, increasing the expression of target genes associated with 
reverse cholesterol transport [74].
 Oxidative-stress-associated inflammation provokes vascular events in atherogenesis, and it 
has been reported that vascular cells in atheroma produce an excess of ROS, which may lead to 
MMP over-expression and activation, in particular macrophage-derived ROS [76-79]. It has also 
been shown that an oxysterol mixture of composition similar to that found in advanced human 
carotid plaques is able to induce MMP-9 expression in U937 cells through ROS over-production; 
this leads to activation of ERK and c-Jun N-terminal kinase (JNK) signaling via PKC and, 
consequently, enhancement of DNA binding of NF-κB and activator protein (AP)-1. These findings 
emerged using specific inhibitors, siRNAs, or specific antibodies. The involvement of ROS in 
MMP-9 up-regulation has also been proven by pre-treating U937 cells with quercetin or with 
EGCG, which are both flavonoids acting as antioxidants [16].
The increased production of PGE2 also appears to be involved in MMP production in the 
progression and rupture of atherosclerotic plaques. Co-localization of COX-2 and PGES was 
demonstrated in symptomatic lesions and associated with acute ischemic syndromes, presumably 
due to MMP-induced plaque rupture [15,44]. This observation was confirmed by the finding of 
concomitant higher expressions of COX-2, PGES, MMP-2 and MMP-9, in specimens from carotid 
lesions of patients with transient ischemic attack or stroke, compared with specimens from 
asymptomatic patients [15]. These molecules co-localize in activated macrophages, which are their 
major source. Moreover, co-distribution of COX-2 and MMPs was found in advanced 
atherosclerotic plaques, in a study on hypercholesterolemic rabbits whose pathological features are 
relevant to human atherosclerosis [80]. The final evidence that induction of COX-2/mPGES 
expression is associated with MMP-induced plaque rupture comes from human patients with 
symptomatic carotid artery stenosis: administration of simvastatin decreases inflammation and 
inhibits both COX-2/mPGES and MMP expression, and in turn contributes to plaque stabilization 
[81]. It has been also reported that PGE2 is capable of inducing expression and activity of MMP-2 
and MMP-9 in plaque macrophages, through a PGE2/cAMP-dependent pathway [18]. Of note, 
incubation of macrophages with the selective COX-2 inhibitor NS-398 blocks MMP-9 expression. 
Moreover, PGE2 and MMP-9 expression by COX-2-/- macrophages was markedly lower than by 
either COX-2+/- or COX-2+/+ macrophages [82]. The association between COX-2/PGE2 and MMPs 
was also confirmed in animal models, by inhibiting or deleting the enzymes involved in the 
biosynthesis pathway of PGE2 [83,84].
Expression of COX-2 and MMP-9 is also mediated by ROS through PKC activity, one of its 
potential down-stream targets, in response to different stimuli [85,86]. Indeed, conventional PKCα 
and PKCβ1 appear to be involved in the signal transduction up-stream of COX-2 and MMP-9, as 
demonstrated upon their inhibition in human monocytes incubated with hydroxytyrosol, an olive oil 
polyphenol with anti-inflammatory properties [87]. 
In addition to increased biosynthesis of PGE2-dependent MMPs in the setting of 
atherosclerotic plaques, PGE2 also stimulates cytokine release by vascular cells; inflammatory 
cytokines, in turn, can directly enhance the synthesis of MMPs in activated macrophages [68]. 
Clearly, all these events play critical roles in enhancing and sustaining a vicious circle, which might 
result in plaque rupture.
The in vitro data found here are in agreement with the latter considerations. Expression and 
protein levels of MMP-9 were significantly increased in cells incubated with 27-OH or HNE. It can 
be hypothesized that the effect of both oxidized lipids on MMP-9 up-regulation might be due to up-
regulation of COX-2/mPGES-1, leading to PGE2 production and to pro-inflammatory cytokine 
release. This hypothesis is supported by the evidence that, after preincubation of U937 cells with 
NS-398, a specific inhibitor of the inducible COX-2 enzyme, or with EGCG, an anti-inflammatory 
polyphenol, both expression and protein levels of MMP-9 were markedly decreased (Fig. 6). 
The findings confirm the link between the inducible functionally coupled COX-2/mPGSE-1 
and plaque instability, based on the increased release of MMP-9 by macrophages incubated with 
27-OH or with HNE, the most representative oxidized lipids in the atherosclerotic plaque. The 
increased production of MMP-9 seems to be due to the increase release of PGE2 and pro-
inflammatory cytokines, such as IL-8, IL-1, and TNF-. In connection with the latter point, the 
importance of these cytokines in regulating the protease levels induced by the two oxidized lipids 
has also been demonstrated elsewhere [17].
The data reported here, which are in agreement with other studies, indicate a key role for 
COX-2/mPGES-1-generated PGE2 in atherosclerotic plaque development and instability. These 
inducible enzymes may thus be potential targets for the development of new anti-inflammatory 
therapeutic agents aimed at increasing the stability of vulnerable plaques. Besides the classical 
drugs, new natural anti-inflammatory drugs and/or selective COX-2 inhibitors may offer new 
therapeutic approaches, in the hope that these agents may provide a good efficacy while not 
producing side effects. 
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Legends of figures
Fig. 1. 27-OH and HNE induce mPGES-1 and COX-2 levels. U937 cells were treated with 27-OH 
(6 μM) or HNE (5 μM) and (A) COX-2 protein levels were analyzed by Western blotting after 24 h 
of incubation. One blot representative of three experiments is shown. The histograms represent the 
mean values ± SD of three experiments; COX-2 was normalized against the corresponding -actin 
levels and expressed as a percentage of the control (untreated cells). **p<0.01 and *p<0.05 vs. 
control. (B) Gene expression of mPGES-1 was quantified by real-time RT-PCR in cells treated for 
up to 6 h with 27-OH or HNE. The histograms represent the mean values ± SD of three 
experiments, expressed as fold induction versus control. Data were normalized to corresponding -
actin levels. ***p<0.001, and *p<0.05 vs. control. (C) After 24 h cell treatment, mPGES-1 protein 
levels were detected by confocal laser microscopy using a FITC-conjugated secondary antibody 
(488-nm exciting laser band and emission passing through a long-pass 505-550 filter, lens 
40x/0.75). The images are representative of three experiments.
Fig. 2. Release of PGE2 following activation of mPGES-1/COX-2 pathway by 27-OH and HNE. 
U937 cells were incubated for 24 h with 27-OH (6 μM) or HNE (5 μM) and PGE2 levels were 
quantified in the medium by enzyme immunoassay (EIA). The histogram represents the values ± 
SD of three experiments.  PGE2 concentrations (pg/mg total protein) were extrapolated from the 
standard curve. **p<0.01, and *p<0.05 vs. control.
Fig. 3. Effect of 27-OH and HNE on nitric oxide production. U937 cells were treated with 27-OH 
(6 μM) or HNE (5 μM) and (A) iNOS expression levels were quantified by real-time RT-PCR after 
6 h cell incubation. The histograms represent the mean values ± SD of three experiments, expressed 
as fold induction versus control. Data were normalized to corresponding -actin levels. **p<0.01, 
and *p<0.05 vs. control. (B) NO production in cell medium was evaluated by Griess reaction after 
48 h cell treatment. The histograms represent mean values ± SD of three experiments, expressed as 
fold induction versus control. NO levels expressed as M were extrapolated from nitrite standard 
curve. **p<0.05 vs. control.
Fig. 4. EGCG reduces mPGES-1 levels induced by the oxidized lipids. U937 cells were pretreated 
for 1 h with 10 M epigallocatechin gallate (EGCG) and then for 6 h with 27-OH (6 μM) or HNE 
(5 μM). mPGES-1 expression was quantified by real-time RT-PCR. The histograms represent mean 
values ± SD of three experiments, expressed as fold induction versus control. Data were normalized 
to corresponding -actin levels. ***p<0.001, and **p<0.01 vs. control; §§§p<0.001 vs. 27-OH; 
###p<0.001 vs. HNE.
Fig. 5. Inhibition of COX-2 and cell pretreatment with the anti-inflammatory EGCG decrease the 
inflammatory cytokine release induced by 27-OH or HNE. Cells were pretreated for 1 h with 25 M 
NS-398 or with 10 M EGCG and (A) expression of IL-8, IL-1, and TNF- was quantified by 
real-time RT-PCR after 6 h cell treatment with 27-OH (6 μM) or HNE (5 μM). The histograms 
represent mean values ± SD of three experiments, expressed as fold induction versus control 
(untreated cells) and normalized to -actin. **p<0.01, and *p<0.05 vs. control; §§§p<0.001, 
§§p<0.01, and §p<0.05 vs. 27-OH; ##p<0.01, and #p<0.05 vs. HNE. (B) After 24 h cell incubation 
with 27-OH or HNE, immunopositive cells were detected by confocal laser microscopy: IL-8 and 
IL-1 using a TRITC-conjugated secondary antibody (532-nm exciting laser band, 572-nm long-
pass emission filter, and 40x/0.75 lens); TNF- using a FITC-conjugated secondary antibody (488-
nm exciting laser band and emission passing through a long-pass 505-550 filter, lens 40x/0.75). The 
images are representative of three experiments.
Fig. 6. COX-2 inhibition and EGCG cell preincubation decrease MMP-9 levels. Cells were 
pretreated for 1 h with 25 M NS-398 or with 10 M EGCG and then with 27-OH (6 μM) or with 
HNE (5 μM) for 24 h. (A) MMP-9 gene expression was evaluated by real-time RT-PCR. The 
histograms represent mean values ± SD of three experiments, expressed as fold induction versus 
control and normalized to -actin. ***p<0.001, and *p<0.05 vs. control; §§§p<0.001 vs. 27-OH; 
#p<0.05 vs. HNE. (B) MMP-9 protein levels were analyzed using the ELISA method after 48 h of 
cell incubation with 27-OH or HNE. MMP-9 concentrations (pg/ml) were extrapolated from the 
standard curve. The histograms represent mean values ± SD of three experiments.  **p<0.01, and 
*p<0.05 vs. control; §§p<0.01 vs. 27-OH; ###p<0.001 vs. HNE.
Highlights 
27-OH and HNE stimulate inflammation by COX-2/mPGES-1 axis and PGE2 release.
27-OH and HNE induce NO production through iNOS up-regulation. 
Inflammation promoted by 27-OH and HNE may be involved in plaque instability.
Inhibition of inflammation induced by 27-OH and HNE reduces MMP-9 up-regulation.
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Abstract
Atherosclerosis is currently understood to be mainly the consequence of a complicated 
inflammatory process at the different stages of plaque development. Among the several 
inflammatory molecules involved, up-regulation of the functional cyclooxygenase 2/membrane-
bound prostaglandin E synthase 1 (COX-2/mPGES-1) axis plays a key role in plaque development. 
Excessive production of oxidized lipids, following low-density lipoprotein (LDL) oxidation, is a 
characteristic feature of atherosclerosis. Among LDLs, the oxysterol 27-hydroxycholesterol (27-
OH) and the aldehyde 4-hydroxynonenal (HNE) substantially accumulate in the atherosclerotic 
plaque, contributing to its progression and instability through a variety of processes. This study 
shows that 27-OH and HNE promote up-regulation of both the inducible enzymes COX-2 and 
mPGES-1, leading to increased production of prostaglandin (PG) E2 and inducible nitric oxide 
synthase, and the subsequent release of nitric oxide in human promonocytic U937 cells. The study 
also examined the potential involvement of the functionally coupled COX-2/mPGES-1 in 
enhancing the production of certain pro-inflammatory cytokines and of matrix metalloproteinase 9 
by U937 cells. This enhancement is presumably due to the induction of PGE2 synthesis, as a result 
of the up-regulation of the COX-2/mPGES-1, stimulated by the two oxidized lipids, 27-OH and 
HNE. Induction of PGE2 synthesis might thus be a mechanism of plaque instability and eventual 
rupture, contributing to matrix metalloproteinase production by activated macrophages. 
Keywords: Atherosclerosis; Inflammation, Plaque instability; 27-Hydroxycholesterol; 4-
Hydroxynonenal. 
Abbreviations: 27-OH, 27-hydroxycholesterol; COX-2, cyclooxygenase-2; EC, endothelial cell; 
EGCG, epigallocatechin gallate; ERK, extracellular signal-regulated kinases; HNE, 4-
hydroxynonenal; IL, interleukin; iNOS, inducible nitric oxide synthase; LDL, low density 
lipoprotein; LXR, liver X receptor; MMP, matrix metalloproteinase; mPGES-1, membrane-bound 
prostaglandin E synthase-1; NF-B, nuclear factor-B; NO, nitric oxide; oxLDL, oxidized LDL; 
PG, prostaglandin; PK, protein kinase; ROS, reactive oxygen species; SMC, smooth muscle cell; 
TIMP, tissue inhibitor of MMP; TLR4, Toll-like receptor 4; TNF-, tumor necrosis factor. 
1. Introduction
Atherosclerosis is a complex chronic inflammatory disease of the vessel wall. Inflammation, 
as well as innate and adaptive immune responses, and oxidative stress play a central role in all 
stages of atherosclerosis including the transition of stable atherosclerotic plaques to unstable 
plaques [1,2]. 
Development of atherosclerotic lesions is preceded by impaired vascular endothelium 
function which favors the retention and accumulation of low-density lipoproteins (LDLs) in the 
sub-endothelial space by specific proteins of extracellular matrix, including collagen and 
proteoglycan.  Here, the lipid moieties of LDL undergo lipid peroxidation resulting in the release of 
various reactive oxidized lipids, including aldehydes, cholesterol oxidation products, and oxidized 
phospholipids. Many studies have demonstrated that accumulation of plaque lipids enhances plaque 
formation, supporting the concept that the plaque is atherogenic. Oxidized LDLs (oxLDLs), which 
accumulate progressively in atherosclerotic lesions, stimulate smooth muscle cell (SMC) 
differentiation and proliferation, monocyte/macrophage recruitment and differentiation, platelet 
aggregation, up-regulation of leukocyte adhesion molecules, and matrix metalloproteinase (MMP) 
activation. Finally, the intercellular cross-talk that occurs among vascular cells leads to a 
fibroproliferative response. During this response, the extracellular matrix components, released by 
differentiated SMCs, play a key role in plaque formation and progression, providing the structural 
integrity of the plaque itself, as well as contributing to cell migration and proliferation [1]. 
In particular, the interaction between oxLDLs and monocyte/macrophage plays predominant 
roles during initiation and progression of atherosclerosis. Activated macrophages not only take up 
the oxLDLs through the scavenger receptor CD36 to form lipid-loaded foam cells, but also release 
pro-inflammatory molecules, such as cytokines, chemokines, and adhesion molecules [1]; the 
release of inflammatory molecules induces an inflammatory state, with subsequent activation of the 
other arterial wall cells, resulting in a lesion that is unstable and prone to rupture when exposed to 
increasing hemodynamic stress. Plaques vulnerable to rupture - the major cause of acute coronary 
syndrome - are characterized by a lipid-rich necrotic core, accumulation of inflammatory cells, and 
fibrous cap weakening, due both to ongoing inflammation and to an imbalance between 
extracellular matrix synthesis and degradation [3-6].
Of the inflammatory molecules involved, cyclooxygenase 2 (COX-2), which is an inducible 
enzyme and overexpressed by activated macrophages in atherosclerotic plaques, may participate in 
the pathogenesis of plaque progression and instability through a variety of processes. These 
comprise activation of chemotaxis, induction of vascular permeability, propagation of inflammatory 
molecules, stimulation of SMC migration, and the resultant induction of itself. Thus COX-2 is 
responsible for the production of eicosanoids, mainly prostaglandin (PG) E2, in inflammatory 
diseases. PGE2 is formed from arachidonic acid via the COX-2-catalyzed formation of PGH2 and 
further transformation by PGE synthases. The isomerization of the endoperoxide PGH2 to PGE2 is 
catalyzed by three different PGH synthases: a cytosolic PGE synthase (cPGES), and two 
membrane-bound PGE synthases (mPGES-1 and mPGES-2). mPGES-1 is mainly an induced 
isomerase, and uses COX-2-derived endoperoxide; it is therefore up-regulated in response to 
various pro-inflammatory stimuli, with a concomitant increased expression of COX-2 [7-9].
Expression of inducible nitric oxide synthase (iNOS) also occurs in conditions of inflammation, and 
produces a large amount of nitric oxide (NO), which contributes to the up-regulation of COX-2 and 
to the subsequent release of PGE2 upon direct interaction with the COX-2 enzyme. A crucial link 
between iNOS and COX-2 pathway has thus been suggested [10-12].
Much evidence deriving from in vitro and ex vivo studies has implicated MMPs, mainly 
MMP-2 and MMP-9, in plaque instability and rupture, because of their ability to degrade all 
macromolecular constituents of the extracellular matrix [13-17]. Induction of expression and 
activity of MMP-2 and MMP-9 by activated macrophages has been shown to occur through a 
PGE2/cAMP-dependent pathway, involving the simultaneous up-regulation of COX-2 and mPGES-
1 [15,18]. It has been shown that these two enzymes, COX-2 and mPGES-1, are simultaneously up-
regulated by pro-inflammatory stimuli, such as the release of growth factors and cytokines [19]. 
The enhanced production of MMPs in vulnerable regions of unstable atherosclerotic plaques 
may, thus, be due to the increased release of PGE2, due in turn to induction of the functionally 
COX-2/mPGES-1 axis by inflammatory stimuli. In addition to increased biosynthesis of PGE2-
dependent MMPs in the atherosclerotic plaque setting, PGE2 can also amplify the release of 
cytokines, and inflammatory cytokines can directly enhance the synthesis of MMPs in activated 
macrophages [20,21]. Clearly, all these events play critical roles in enhancing and sustaining a 
vicious circle that might result in plaque rupture. Of note, among the MMPs, MMP-9 has been 
consistently implicated in plaque instability and rupture [22]. Various inflammatory molecules, in 
particular PGE2 and cytokines, as well as oxidative stress molecules such as reactive oxygen species 
(ROS), play crucial roles in the cross-talk among vascular cells leading to up-regulation of MMPs 
[23,24].  
It has been extensively demonstrated that lipids carried by oxLDLs activate monocytes and 
macrophages during atherosclerotic inflammatory processes, and that they contribute to increasing 
and sustaining pro-inflammatory molecule production [25-27].
Among the oxidized plaque lipids, the oxysterol 27-hydroxycholesterol (27-OH), a 
cholesterol oxidation product, and the aldehyde 4-hydroxynonenal (HNE), one of the more reactive 
end products of polyunsaturated fatty acid (PUFA) peroxidation, play key roles in the pathogenesis 
of atherosclerosis. They act by stimulating various signal transduction pathways that are involved 
both in the inflammatory response and in the immune response and oxidative stress [28-31]. 
Based on these considerations, it was decided to investigate whether the oxysterol 27-OH 
and the aldehyde HNE, which substantially accumulate in the atherosclerotic plaque, may up-
regulate COX-2 and mPGES-1, resulting in the induction of PGE2 synthesis; this might be a 
mechanism of plaque instability and eventual rupture, contributing to the production of 
inflammatory cytokines and MMPs by activated macrophages. The study found an enhanced 
production of certain pro-inflammatory cytokines and of MMP-9, presumably due to the induction 
of PGE2 synthesis, as a result of the up-regulation of the functionally coupled inducible COX-
2/mPGES-1, in human promonocytic U937 cells stimulated by the oxidized lipids 27-OH and HNE.
2. Methods
2.1. Cell culture and treatments
The human promonocytic cell line U937 was cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (Invitrogen, Life Technologies, Monza, Italy), 100 U/mL penicillin, 
100 μg/mL streptomycin, and 2 mM glutamine (Sigma-Aldrich, Milan, Italy) at 37 °C with 5% 
CO2. The cells were dispensed at 1x106/ml and made quiescent through overnight incubation in 
serum-free medium. They were then placed in RPMI 1640 medium with 2% fetal bovine serum and 
treated with 6 μM 27-OH (Avanti Polarlipids, Alabaster, AL, USA) or in serum-free RPMI 1640 
medium and treated with 5 μM HNE (Alexis, Vinci-Biochem, Vinci, Italy). In certain experiments, 
cells were pretreated for 1 h with 25 μM of NS-398, a specific inhibitor of COX-2 or with 10 μM 
epigallocatechin gallate (EGCG) (Sigma-Aldrich). Final concentrations and incubation times for all 
experiments are given in the figure legends.
2.2. RNA extraction
Total RNA was extracted from cells using TRIzol reagent (Applied Biosystems, Thermo 
Fisher Scientific, Monza, Italy), following the manufacturer's instructions, after treatment with 27-
OH or HNE. RNA was dissolved in RNase-free water with RNase inhibitors (RNase SUPERase-In; 
Applied Biosystems, Thermo Fisher Scientific). The amount and purity (A260/A280 ratio) of the 
extracted RNA were assessed spectrophotometrically.
2.3. cDNA preparation and real-time RT-PCR
cDNA was synthesized by reverse transcription from 2 μg RNA with a commercial kit and 
random primers (High-Capacity cDNA reverse transcription kit; Applied Biosystems, Thermo 
Fisher Scientific), following the manufacturer's instructions. Singleplex real-time RT-PCR was 
performed on 40 ng of cDNA using TaqMan gene expression assay kits prepared for human 
mPGES-1, iNOS, interleukin-8 (IL-8), IL-1, tumor necrosis factor- (TNF-), MMP-9, and -
actin and TaqMan Fast Universal PCR master mix, and analyzed by a 7500 Fast real-time PCR 
system (Applied Biosystems, Thermo Fisher Scientific). The oligonucleotide sequences are not 
revealed by the manufacturer because of proprietary interests. The cycling parameters were as 
follows: 20 s at 95 °C for AmpErase UNG activation, 3 s at 95 °C for AmpliTaq Gold DNA 
polymerase activation, and 40 cycles of 3 s each at 95 °C (melting) and 30 s at 60 °C 
(annealing/extension). The fractional cycle number at which fluorescence passes the threshold in 
the amplification plot of fluorescence signal versus cycle number was determined for each gene 
considered. The results were then normalized to the expression of -actin, as housekeeping gene. 
Target gene expression was quantified relatively with a mathematical method proposed by Livak 
and Schmittgen [32].
2.4. Analysis of mPGES-1, IL-8, IL-1, and TNF- by immunofluorescence, and detection by 
confocal laser microscopy 
After treatments, cells were transferred onto glass slides (8x104 cells/slide) by 
cytocentrifugation. Specimens were fixed in cold methanol for 10 min and permeabilized for 10 
min with 0.1 M PBS-0.4% Triton X-100 solution. Cells were then incubated with a 100 mM sodium 
cyanoborohydride reducing agent for 10 min at 37 °C. After blocking nonspecific sites of binding 
with 0.1 M PBS containing 5% goat serum, 3% BSA, and 0.3% Tween 20, slides were incubated in 
the presence of primary antibodies against mPGES-1 (1:200), IL-8 (1:100), IL-1 (1:50), and TNF-
 (1:50) (Santa Cruz Biotechnology, Dallas, TX, USA) and then with specific secondary antibodies 
(1:200) conjugated with fluorescein isothiocyanate (FITC) or tetramethylrhodamine isothiocyanate 
(TRITC) fluorochromes (Alexa Fluor, Molecular Probes, Thermo Fischer Scientific). Slides 
mounted with glycerol and distilled water (1:1) were observed through an LSM 510 confocal laser 
microscope (Carl Zeiss SpA, Arese, Milan, Italy) equipped with an inverted microscope with Plan-
NEOFLUAR lenses (40 x/0.75).
2.5. Analysis of COX-2 by Western blotting
Cells were lysed in ice-cold buffer containing 20 mM Hepes, pH 7.9, 0.35M NaCl, 20% 
glycerol, 1% Igepal CA-630, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, and protease inhibitors 
and centrifuged at 14000 rpm for 15 min. For COX-2 protein, 50 μg of total proteins were boiled 
for 5 min in Laemmli buffer and separated in 10% denaturing SDS/polyacrylamide gels followed by 
transfer to nitrocellulose membranes. Filters were blocked with 5% nonfat dried milk in Tris-
buffered saline (TBS) 1X-0.05% Tween 20 for 1 h at room temperature and incubated overnight at 
4 °C with the appropriate primary antibody against COX-2 (1:250) diluted in 5% nonfat dried milk 
or in 1% bovine serum albumin in TBS 1X-0.05% Tween 20, followed by specific horseradish 
peroxidase (HRP)-conjugated secondary antibody for 2 h at room temperature (Santa Cruz 
Biotechnology). The membranes were then stripped with the Restore Western blot stripping buffer 
(Pierce Biotechnology, Rockford, IL, USA) and again immunoblotted with anti-actin primary 
antibody (1:6000) (Sigma-Aldrich) and then incubated with a specific secondary antibody, as 
described above. Proteins were detected using the Clarity Western ECL subtrate (Bio-Rad 
Laboratoires, Segrate, Milan, Italy) following the manufacturer's protocol. The immunoreactive 
bands were scanned and subjected to densitometric analysis using the Image Tool software package. 
The results are expressed in relative units, determined by normalizing the density of each band of 
the corresponding reference protein band.
2.6. NO measurement by Griess reaction
NO concentration was determined by quantifying the stable end-product of NO, i.e. nitrite. 
A colorimetric assay kit (Griess Reagent Kit for Nitrite Determination) based on the Griess reaction 
was used following the manufacturer’s instructions (Molecular Probes, Thermo Fisher Scientific). 
Briefly, 80 µl of supernatant collected after 48 h cell treatment were sequentially mixed with 80 µl 
of a 1% solution of sulfanilic acid in 5% phosphoric acid and 80 µl of a 0.1% solution of N-(1-
naphthyl) ethylenediamine dihydrochloride. The mixture was kept at room temperature for 30 min. 
The absorbance was measured at 550 nm in a microplate reader. Nitrite concentrations were 
calculated from a standard curve obtained by diluting the sodium nitrite stock solution contained in 
the kit in cell medium.
2.7. PGE2 determination by enzyme immunoassay (EIA)
After U937 cell treatment with 6 M 27-OH or 5 M HNE for 24 h, supernatants were 
collected, centrifuged, and stored at -80 °C. Supernatants were purified using a C-18 column, as per 
the manufacturer’s protocol. After evaporation of ethyl acetate under nitrogen stream, and 
resuspension of sample in EIA buffer, levels of PGE2 were measured using a commercially-
available enzyme immunoassay kit (Prostaglandin E2 ELISA Kit-monoclonal) following the 
manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI, USA). Absorbance was measured 
at 415 nm in a microplate reader. 
2.8. Evaluation of MMP-9 protein levels by enzyme linked immunosorbent assay (ELISA)
After treatments, cells were lysed and cytosolic proteins were stored for ELISA detection. 
MMP-9 levels were quantified using the DuoSet ELISA kit (R&D System, MN, USA), following 
the manufacturer's instructions. The plates were read at 450 nm with wavelength correction of 550 
nm in a microplate reader (Model 680 Microplate Reader, Bio-Rad). The concentrations of MMP-9 
were extrapolated from the standard curve.
2.9. Statistical analysis
All values are expressed as means ± standard deviation (SD). Statistical analysis of the data 
was by one-way ANOVA with Bonferroni's post-test for multiple comparisons. Differences with p< 
0.05 were considered statistically significant. Statistical calculations were done with the GraphPad 
InStat3 software package (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. The lipid oxidation products 27-OH and HNE up-regulate both COX-2 and mPGES-1 in U937 
cells
To investigate whether 27-OH and HNE are involved in the simultaneous up-regulation of 
COX-2 and mPGES-1, human promonocytic U937 cells were incubated with these two oxidized 
lipids. The oxysterol 27-OH was used at 6 M, a concentration mimicking the amount found in 
atherosclerotic plaques [33], while the aldehyde HNE was used at a concentration of 5 M, which is 
below that found in inflamed and diseased tissues [34].
The effects of 27-OH and HNE on the protein levels of COX-2 were analyzed by Western 
blotting, while the expression and synthesis of m-PGES-1 were quantified by real-time RT-PCR 
and confocal laser microscopy, respectively. 
Both oxidized lipids significantly induced COX-2 protein levels after 24 h cell treatment 
(Fig. 1 A), compared to untreated cells (control). Further, an approximately time-dependent increase 
of mPGES-1 mRNA levels was observed from 2 to 6 h of treatment, compared with untreated cells 
(control), in particular after cell treatment with HNE (5 M). However, both oxidized lipids 
significantly induced mPGES-1 expression after 6 h cell treatment (Fig. 1B). An increase of 
mPGSE-1 protein levels was observed by immunofluorescence analysis, using a confocal laser 
microscope, after 24 h cell incubation with either 27-OH or HNE (Fig. 1C).
3.2. Induction of PGE2 production by U937 cells treated with 27-OH or HNE
COX-2 and mPGES-1, induced in response to inflammatory stimuli, are involved in 
prostaglandin generation in inflammatory diseases, including atherosclerosis [7,9]. Among 
prostaglandins, PGE2 plays a key role in the setting of human atherogenesis.
The effects of 27-OH (6 M) and HNE (5 M) on PGE2 production by human promonocytic 
U937 cells was checked by ELISA after 24 h treatment. PGE2 production, as a result of induction of 
the functional COX-2/mPGES-1 axis, was consistently induced by both compounds compared to 
untreated cells (control) (Fig. 2). As noticed in previous results concerning COX-2/mPGES-1 up-
regulation, again in this case the strongest effect on PGE2 production occurred in cells treated with 
HNE. 
3.3. Both 27-OH and HNE up-regulate iNOS and NO
Expression of iNOS occurs in condition of inflammation, and its activation promotes and 
maintains the production of NO. Cross-communication between iNOS and COX-2 has been 
suggested, since NO contributes to the up-regulation of COX-2 and the subsequent release of PGE2; 
these play crucial roles in plaque instability. 
To investigate whether 27-OH or HNE stimulate iNOS expression, U937 cells were 
incubated with 6 M 27-OH or 5 M HNE for up to 6 h. A time-dependent increase of iNOS 
mRNA levels was observed from 2 to 6 h of cell treatment with HNE compared with untreated cells 
(control), while in cells incubated with 27-OH a significant increase of iNOS expression occured 
only after 6 h treatment (Fig. 3A).  As a consequence of the increased expression of iNOS, an 
increased production of NO (in terms of nitrite) was then observed using the colorimetric assay kit, 
in cells treated for 48 h with either compound (Fig. 3B).
3.4. Down-regulation of mPGES-1 by the anti-inflammatory effect exerted by EGCG in U937 cells 
treated with 27-OH or HNE 
The pathophysiological role of the functional COX-2/mPGES-1 axis also depends on the 
induction of mPGES-1 expression by pro-inflammatory stimuli [35,36]. 
To determine whether natural compounds, such as polyphenols, may act as anti-
inflammatory molecules, cells were pretreated with the flavanol EGCG (10 M). A significant 
reduction in mPGES-1 expression was observed in the presence of EGCG after 6 h cell incubation 
with 27-OH (6 M) or HNE (5 M), compared with cells treated with 27-OH or HNE alone (Fig. 
4). EGCG may act by preventing the inflammatory state that is generated in U937 cells upon 
incubation with the oxysterol or the aldehyde; this would reduce the expression of COX-2 and 
mPGES-1, critical enzymes in the progression of atherosclerotic plaque, and in the formation of 
functionally-coupled COX-2/mPGES-1. 
3.5. Up-regulation of IL-8, IL-1 and TNF- by 27-OH and HNE: implication of functionally-
coupled COX-2/mPGES-1 in cytokine release 
The enhanced PGE2 synthesis as a consequence of COX-2/mPGES-1 induction may amplify 
the release of inflammatory cytokines by activated macrophages. Both PGE2 and inflammatory 
cytokine release contribute to atherosclerotic plaque instability, by increasing MMP production with 
consequent matrix break-down [37,38].
Among the inflammatory cytokines involved in the pathogenesis of atherosclerosis, the 
effect of 6 M 27-OH and of 5 M HNE on IL-8, IL-1, and TNF- expression and synthesis on 
U937 cells was determined by real-time RT-PCR, or by immunofluorescence analysis using a 
confocal laser microscope, respectively.
Expression of all the cytokines considered was significantly increased by 27-OH and HNE 
after 6 h treatment, compared with untreated cells (Fig. 5A). Increased protein levels of these 
inflammatory cytokines were also clearly detected by confocal microscopy after 24 h cell treatment 
(Fig. 5B).
To investigate involvement of the COX-2 pathway and of inflammatory stimuli on IL-8, IL-
1, and TNF- release by U937 cells incubated with 27-OH (6 M) or HNE (5 M), the cells were 
pretreated with 25 M NS-398, a selective inhibitor of COX-2, or with 10 M EGCG, an anti-
inflammatory molecule. Expression (Fig. 5A) and protein levels (Fig. 5B) of all the cytokines 
examined were markedly decreased, supporting the involvement of COX-2/mPGES-1 and of the 
subsequent PGE2 production, in exacerbating the inflammatory state that contributes to plaque 
instability.
3.6. Involvement of COX-2 pathway on up-regulation of MMP-9 by 27-OH and HNE in U937 cells 
The protease MMP-9 plays a fundamental role in the instability and eventual rupture of 
atherosclerotic plaques [20-22]. Its expression and proteolytic activity can be up-regulated by 
different cell signaling pathways, which may be interconnected. Among them, several studies point 
to MMP-9 release occurring through a COX-2/mPGES-1/PGE2 pathway [18,39,40]. 
The effects of 27-OH (6 M) and HNE (5 M) on MMP-9 expression and synthesis were 
thus explored, by real-time RT-PCR after 24 h treatment, and by ELISA after 48 h treatment, 
respectively. Of note, the ELISA kit employed recognizes both inactive and active forms of MMP-
9. In human promonocytic U937 cells, MMP-9 expression (Fig. 6A) and protein levels (Fig. 6B) 
were consistently induced both by the oxysterol and by the lipid aldehyde, compared with untreated 
cells (control).
To investigate whether the production of MMP-9 by U937 cells occurs through a COX-2-
dependent pathway, cells were pretreated with NS-398 (25 M) or with EGCG (10 M). With the 
specific COX-2 inhibitor or the natural anti-inflammatory flavanol, the up-regulation of MMP-9 
expression and synthesis induced by 27-OH or HNE was significantly decreased compared with 
control cells (Fig. 6A,B).
These data support the potential role of COX-2/mPGES-1 and, presumably, of PGE2 in MMP-9 up-
regulation, in enhancing plaque instability.
4. Discussion 
Current understanding of the pathogenesis of atherosclerosis suggests the involvement of 
complex mechanisms that go beyond the mere storage of oxLDLs: it is now clear that inflammation 
plays a critical role in the cascade of events that lead to atherosclerotic plaque rupture [1,3,4]. 
OxLDLs can stimulate inflammatory activation of vascular cells acting as “danger associated 
molecular patterns” (DAMPs). They also provide oxidation-specific epitopes that are recognized by 
innate natural immunoglobulin M (IgM) antibodies, as well as by C-reactive protein and 
complement protein system. Although the natural IgM antibodies can facilitate the clearance of 
oxLDLs, the overstimulation of the innate immune system can lead to the development of an 
autoimmune response that includes both immunoglobulin class switching (e.g. to IgG), affinity 
maturation of antibodies, and the release of T-lymphocyte response to oxLDLs. All these events can 
contribute to maintain inflammation and the progression of atherosclerotic lesions [41]. In this 
connection, while the IgM anti-oxLDLs are able to reduce the atherosclerotic events, in turn the IgG 
antibodies stimulate the secretion of pro-inflammatory cytokines contributing to oxLDL 
accumulation at sub-endothelial sites and atherosclerotic plaque formation [42]. 
As part of the inflammatory response within atheroma, both the inducible enzymes, COX-2 
and mPGES-1, are simultaneously up-regulated in activated macrophages, by inflammatory stimuli 
including cytokines; this leads to the subsequent production of eicosanoids, mainly PGE2 which 
participate in the pathogenesis of atherosclerotic plaque formation and instability through a variety 
of processes [7,19,43-45].
Both pharmacologic and direct genetic evidence implicate COX-2 over-expression in 
atherosclerotic lesion formation [21,46,47]. COX-2 has been detected in the fatty streaks of both 
humans and mice, and its pro-atherogenic role has been demonstrated using rofecoxib, a highly 
selective COX-2 inhibitor, which reduced the formation of fatty streaks in the vascular wall [46,48]. 
COX-2 is also extensively expressed, alongside mPGES-1, by activated macrophages within 
advanced human atherosclerotic plaques, and to a lesser extent by SMCs and ECs, whereas low or 
even undetectable levels of COX-2 are found in normal human arteries. Of note, macrophages of 
the shoulder region contain most of the COX-2 protein level within the atherosclerotic lesion 
[15,44]. However, it has been observed that macrophage foam cells of atherosclerotic plaques do 
not express COX-2, thus suggesting that the enzyme is down-regulated in mature foam cells 
[15,46].  Interestingly, it has also been shown that mice lacking COX-2, mice expressing modified 
COX-2, and mice treated with a COX-2 inhibitor, all produce significantly less prostacyclin than 
normal animals whereas thromboxane formation remains unaltered, and the animals develop 
thrombosis and hypertension [49]. Moreover, in mPGES-1 knockout mice, a 30% reduction in 
macrophage foam cells was observed in the atherosclerotic plaques, which also displayed less 
necrosis [50]. 
The enzyme iNOS is also induced by inflammatory stimuli, such as cytokines, and it 
potentially regulates the development of atherosclerosis, thanks to its ability to produce 
peroxynitrite (ONOO-), which contributes to endothelial dysfunction [51], and to produce excess 
NO [11]. The involvement of iNOS up-regulation in the pathogenesis of atherosclerosis is 
supported by the observation, in apolipoprotein E-deficient mice, that genetic iNOS deficiency 
reduced diet-induced atherosclerotic lesion formation [52]. Nanomolar amounts of NO are 
continuously generated by iNOS, which is regulated by many cell types, including macrophages, 
neutrophils, ECs and SMCs. Excess NO can impair cholesterol efflux in macrophage foam cells, 
suggesting that iNOS may reduce plaque healing [53], but it can also contribute to COX-2 up-
regulation, supporting cross-talk among the iNOS/NO/COX-2 pathways, leading to an increased 
release of PGE2 as a consequence of direct interaction with the COX-2 enzyme [11,12]. The 
relationship between iNOS and COX-2 is also supported by the co-localization of iNOS and COX-
2, predominantly in macrophages/foam cells, in both native and transplanted human coronary 
arteries [54]. The enhancing effects of pro-inflammatory cytokines on iNOS and NO expression has 
been demonstrated by inhibiting iNOS and COX-2 induction, using anti-inflammatory steroids that, 
in parallel, reduced both NO and PGE2 generation [55,56], as well as by employing the selective 
iNOS inhibitor aminoguanidine [57]. 
It has also been shown that oxLDLs induce COX-2 expression by extracellular signal-
regulated kinase (ERK) activation, and that COX-2 is expressed in atherosclerotic lesions, where it 
promotes inflammation [15,58]. Increased COX-2 expression was found in LDL receptor-/- mice, in 
which it contributed to atherogenesis [46]. Oxysterols and aldehydes play a crucial role among 
lipids carried by oxLDLs that activate macrophages, contributing and sustaining inflammation 
during atherosclerotic plaque progression. Of note, it has been demonstrated that accumulation in 
the vessel walls of foam cell-derived HNE might promote vascular EC senescence [59]. Moreover, 
HNE accumulate in an age-related manner in the arterial walls contributing to elastin degradation 
thus favoring the development of the atherosclerotic lesions [60]. However, in a recent study, it has 
been reported that low levels of the aldehydes HNE and 4-hydroxy-2E-,6Z-dodecadienal (4-HDDE) 
induce an hormetic response which counteract stressful stimuli allowing vascular endothelial cells 
to restore their normal functions [61]. 
The present study demonstrated that 27-OH, the most abundant circulating oxysterol, and 
HNE, the most reactive aldehyde, both of which accumulate markedly in atherosclerotic plaques, 
are able to increase COX-2 (Fig. 1A) and mPGES-1 (Fig. 1B and C) levels, resulting in the 
induction of PGE2 release (Fig. 3) in human promonocytic U937 cells. In U937 cells, increased 
iNOS expression (Fig. 2A) and NO levels (Fig. 2B) were also observed after cell treatment with 27-
OH or with HNE. The data indicate that oxidized lipids may stimulate these inducible enzymes, 
thus triggering release of their products which contribute to inflammation and plaque instability.
During inflammation, abundant pro-inflammatory cytokines are produced by macrophages, 
following activation of several mechanisms, including up-regulation of COX-2/mPGES-1. In turn, 
cytokines are themselves responsible for both COX-2 and mPGES-1 up-regulation. In particular, it 
has been shown that interferon- (IFN-) in combination with TNF- induces a synergistic increase 
of COX-2 mRNA in human macrophages [19]. Moreover, a mixture of IL-1, TNF-, and IFN- 
enhances the release of PGE2 and COX-2 activity in human pulmonary epithelial cells [62]. IL-1 is 
also a potent inducer of COX-2 expression in various cell types, including osteoblasts [63], while 
stimulation of human microglia with IL-8 effectively increases expression of pro-inflammatory 
cytokines and COX-2 [64]. The expression of mPGES-1 is also markedly increased in various cells 
and tissues by the same pro-inflammatory stimuli (i.e. IL-1, TNF-) involved in COX-2 induction 
[65].
In this connection, it was observed that cell pretreatment with the flavanol EGCG, a 
polyphenol with anti-inflammatory and antioxidant properties, significantly decreased the 
expression of mPGES-1 induced by 27-OH or HNE (Fig. 4). The release of certain cytokines, 
mainly involved in atherosclerotic plaque instability, which is induced by these oxidized lipids, 
markedly decreased in cells preincubated with NS-398, a specific inhibitor of COX-2, or with 
EGCG (Fig. 5). 
Of note, the simultaneous up-regulation of functionally-coupled COX-2/mPGES-1, during 
the inflammatory response in macrophages, may also be due to PGE2 itself, via a positive-feedback 
regulation of both the PGE2-synthesizing enzymes. PGE2 is able to induce transcriptional activation 
of the two enzymes, by over-expressing its receptor EP2, with consequent activation of the 
cAMP/protein kinase A/cAMP-response element-binding protein (cAMP/PKA/CREB) signaling 
pathway [66]. 
With regard to atherosclerotic plaque instability, increased expression and activity of MMPs, 
in particular of MMP-2 and MMP-9, has been observed in unstable human carotid plaques, in 
association with macrophages [13,67]. The increase of MMPs in advanced atherosclerotic plaques 
has the potential to cause acute plaque rupture and the subsequent thrombotic events. Expression 
and proteolytic activities of MMPs are induced by several stimuli or mediators, through activation 
of various interconnected signaling pathways [16,17].
Several cytokines, chemokines, and growth factors regulate MMP expression at the 
transcriptional level, and also regulate their cell release [23,24]. For example, it has been reported 
that IL-1 and IL-8 can release a local imbalance between MMPs and tissue inhibitor of MMPs 
(TIMPs) by inhibiting TIMP-1 expression in macrophages [68,69]. In this connection, in human 
promonocytic U937 cells, it has been demonstrated that the oxysterol 27-OH and the reactive 
aldehyde HNE may promote plaque instability through activation of Toll like receptor 4/nuclear 
factor-κB (TLR4/NF-κB) pathway, which seems to up-regulate MMP-9 by increasing local 
inflammatory cytokine release, or even directly [17]. 27-OH also contributes to inflammation by 
enhancing the production of IL-8 in macrophages through activation of NF-B [70] as well as 
monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1), 
and MMP-9 in THP-1 cells [71]. To confirm that an inflammatory state can contribute to MMP-9 
expression, specific antibodies were used to block the action of IL-8, IL-1, and TNF-, which are 
released following cell treatment with 27-OH or HNE and TLR4/NF-κB pathway activation; both 
MMP-9 mRNA and protein levels were consistently decreased, confirming the importance of these 
cytokines in regulating the protease levels induced by both the oxidized lipids [17]. 
Although 27-OH has been studied for its involvement in pro-inflammatory processes, it is 
now well known that it plays also a role as ligand for liver X receptors (LXRs), transcription factors 
that regulate an array of genes, including genes involved in anti-inflammatory response [72]. The 
dual effect of 27-OH on inflammatory process depends on the fact that it is a weak LXR agonist and 
that 27-OH can bind signaling molecules different from LXRs, thus inducing expression of 
inflammatory markers. Several studies on LXR ligands, deriving from the use of synthetic agonists 
of LXR which fully activate it, demonstrated anti-inflammatory effects of LXR [73]. In this 
connection, treatment with LXR agonists (e.g. T0901317) reduces atherosclerosis in vivo through 
inhibition of various inflammatory gene expression, including TNF-, IL-1, IL-6, COX-2, iNOS, 
and NF-B [74]. Of note, LXR activation induces the expression of genes different from those 
stimulated by endogenous oxysterols. Therefore, although LXR-activating oxysterols might reduce 
inflammation, they can also act by activating opposing pathways and inducing expression of 
inflammation markers independently of LXRs [73]. Another beneficial effect of 27-OH is due to its 
ability to protect human macrophages from cholesterol overload [75] since oxysterols, by binding to 
LXR, might act as “cholesterol sensors”, increasing the expression of target genes associated with 
reverse cholesterol transport [74].
 Oxidative-stress-associated inflammation provokes vascular events in atherogenesis, and it 
has been reported that vascular cells in atheroma produce an excess of ROS, which may lead to 
MMP over-expression and activation, in particular macrophage-derived ROS [76-79]. It has also 
been shown that an oxysterol mixture of composition similar to that found in advanced human 
carotid plaques is able to induce MMP-9 expression in U937 cells through ROS over-production; 
this leads to activation of ERK and c-Jun N-terminal kinase (JNK) signaling via PKC and, 
consequently, enhancement of DNA binding of NF-κB and activator protein (AP)-1. These findings 
emerged using specific inhibitors, siRNAs, or specific antibodies. The involvement of ROS in 
MMP-9 up-regulation has also been proven by pre-treating U937 cells with quercetin or with 
EGCG, which are both flavonoids acting as antioxidants [16].
The increased production of PGE2 also appears to be involved in MMP production in the 
progression and rupture of atherosclerotic plaques. Co-localization of COX-2 and PGES was 
demonstrated in symptomatic lesions and associated with acute ischemic syndromes, presumably 
due to MMP-induced plaque rupture [15,44]. This observation was confirmed by the finding of 
concomitant higher expressions of COX-2, PGES, MMP-2 and MMP-9, in specimens from carotid 
lesions of patients with transient ischemic attack or stroke, compared with specimens from 
asymptomatic patients [15]. These molecules co-localize in activated macrophages, which are their 
major source. Moreover, co-distribution of COX-2 and MMPs was found in advanced 
atherosclerotic plaques, in a study on hypercholesterolemic rabbits whose pathological features are 
relevant to human atherosclerosis [80]. The final evidence that induction of COX-2/mPGES 
expression is associated with MMP-induced plaque rupture comes from human patients with 
symptomatic carotid artery stenosis: administration of simvastatin decreases inflammation and 
inhibits both COX-2/mPGES and MMP expression, and in turn contributes to plaque stabilization 
[81]. It has been also reported that PGE2 is capable of inducing expression and activity of MMP-2 
and MMP-9 in plaque macrophages, through a PGE2/cAMP-dependent pathway [18]. Of note, 
incubation of macrophages with the selective COX-2 inhibitor NS-398 blocks MMP-9 expression. 
Moreover, PGE2 and MMP-9 expression by COX-2-/- macrophages was markedly lower than by 
either COX-2+/- or COX-2+/+ macrophages [82]. The association between COX-2/PGE2 and MMPs 
was also confirmed in animal models, by inhibiting or deleting the enzymes involved in the 
biosynthesis pathway of PGE2 [83,84].
Expression of COX-2 and MMP-9 is also mediated by ROS through PKC activity, one of its 
potential down-stream targets, in response to different stimuli [85,86]. Indeed, conventional PKCα 
and PKCβ1 appear to be involved in the signal transduction up-stream of COX-2 and MMP-9, as 
demonstrated upon their inhibition in human monocytes incubated with hydroxytyrosol, an olive oil 
polyphenol with anti-inflammatory properties [87]. 
In addition to increased biosynthesis of PGE2-dependent MMPs in the setting of 
atherosclerotic plaques, PGE2 also stimulates cytokine release by vascular cells; inflammatory 
cytokines, in turn, can directly enhance the synthesis of MMPs in activated macrophages [68]. 
Clearly, all these events play critical roles in enhancing and sustaining a vicious circle, which might 
result in plaque rupture.
The in vitro data found here are in agreement with the latter considerations. Expression and 
protein levels of MMP-9 were significantly increased in cells incubated with 27-OH or HNE. It can 
be hypothesized that the effect of both oxidized lipids on MMP-9 up-regulation might be due to up-
regulation of COX-2/mPGES-1, leading to PGE2 production and to pro-inflammatory cytokine 
release. This hypothesis is supported by the evidence that, after preincubation of U937 cells with 
NS-398, a specific inhibitor of the inducible COX-2 enzyme, or with EGCG, an anti-inflammatory 
polyphenol, both expression and protein levels of MMP-9 were markedly decreased (Fig. 6). 
The findings confirm the link between the inducible functionally coupled COX-2/mPGSE-1 
and plaque instability, based on the increased release of MMP-9 by macrophages incubated with 
27-OH or with HNE, the most representative oxidized lipids in the atherosclerotic plaque. The 
increased production of MMP-9 seems to be due to the increase release of PGE2 and pro-
inflammatory cytokines, such as IL-8, IL-1, and TNF-. In connection with the latter point, the 
importance of these cytokines in regulating the protease levels induced by the two oxidized lipids 
has also been demonstrated elsewhere [17].
The data reported here, which are in agreement with other studies, indicate a key role for 
COX-2/mPGES-1-generated PGE2 in atherosclerotic plaque development and instability. These 
inducible enzymes may thus be potential targets for the development of new anti-inflammatory 
therapeutic agents aimed at increasing the stability of vulnerable plaques. Besides the classical 
drugs, new natural anti-inflammatory drugs and/or selective COX-2 inhibitors may offer new 
therapeutic approaches, in the hope that these agents may provide a good efficacy while not 
producing side effects. 
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Legends of figures
Fig. 1. 27-OH and HNE induce mPGES-1 and COX-2 levels. U937 cells were treated with 27-OH 
(6 μM) or HNE (5 μM) and (A) COX-2 protein levels were analyzed by Western blotting after 24 h 
of incubation. One blot representative of three experiments is shown. The histograms represent the 
mean values ± SD of three experiments; COX-2 was normalized against the corresponding -actin 
levels and expressed as a percentage of the control (untreated cells). **p<0.01 and *p<0.05 vs. 
control. (B) Gene expression of mPGES-1 was quantified by real-time RT-PCR in cells treated for 
up to 6 h with 27-OH or HNE. The histograms represent the mean values ± SD of three 
experiments, expressed as fold induction versus control. Data were normalized to corresponding -
actin levels. ***p<0.001, and *p<0.05 vs. control. (C) After 24 h cell treatment, mPGES-1 protein 
levels were detected by confocal laser microscopy using a FITC-conjugated secondary antibody 
(488-nm exciting laser band and emission passing through a long-pass 505-550 filter, lens 
40x/0.75). The images are representative of three experiments.
Fig. 2. Release of PGE2 following activation of mPGES-1/COX-2 pathway by 27-OH and HNE. 
U937 cells were incubated for 24 h with 27-OH (6 μM) or HNE (5 μM) and PGE2 levels were 
quantified in the medium by enzyme immunoassay (EIA). The histogram represents the values ± 
SD of three experiments.  PGE2 concentrations (pg/mg total protein) were extrapolated from the 
standard curve. **p<0.01, and *p<0.05 vs. control.
Fig. 3. Effect of 27-OH and HNE on nitric oxide production. U937 cells were treated with 27-OH 
(6 μM) or HNE (5 μM) and (A) iNOS expression levels were quantified by real-time RT-PCR after 
6 h cell incubation. The histograms represent the mean values ± SD of three experiments, expressed 
as fold induction versus control. Data were normalized to corresponding -actin levels. **p<0.01, 
and *p<0.05 vs. control. (B) NO production in cell medium was evaluated by Griess reaction after 
48 h cell treatment. The histograms represent mean values ± SD of three experiments, expressed as 
fold induction versus control. NO levels expressed as M were extrapolated from nitrite standard 
curve. **p<0.05 vs. control.
Fig. 4. EGCG reduces mPGES-1 levels induced by the oxidized lipids. U937 cells were pretreated 
for 1 h with 10 M epigallocatechin gallate (EGCG) and then for 6 h with 27-OH (6 μM) or HNE 
(5 μM). mPGES-1 expression was quantified by real-time RT-PCR. The histograms represent mean 
values ± SD of three experiments, expressed as fold induction versus control. Data were normalized 
to corresponding -actin levels. ***p<0.001, and **p<0.01 vs. control; §§§p<0.001 vs. 27-OH; 
###p<0.001 vs. HNE.
Fig. 5. Inhibition of COX-2 and cell pretreatment with the anti-inflammatory EGCG decrease the 
inflammatory cytokine release induced by 27-OH or HNE. Cells were pretreated for 1 h with 25 M 
NS-398 or with 10 M EGCG and (A) expression of IL-8, IL-1, and TNF- was quantified by 
real-time RT-PCR after 6 h cell treatment with 27-OH (6 μM) or HNE (5 μM). The histograms 
represent mean values ± SD of three experiments, expressed as fold induction versus control 
(untreated cells) and normalized to -actin. **p<0.01, and *p<0.05 vs. control; §§§p<0.001, 
§§p<0.01, and §p<0.05 vs. 27-OH; ##p<0.01, and #p<0.05 vs. HNE. (B) After 24 h cell incubation 
with 27-OH or HNE, immunopositive cells were detected by confocal laser microscopy: IL-8 and 
IL-1 using a TRITC-conjugated secondary antibody (532-nm exciting laser band, 572-nm long-
pass emission filter, and 40x/0.75 lens); TNF- using a FITC-conjugated secondary antibody (488-
nm exciting laser band and emission passing through a long-pass 505-550 filter, lens 40x/0.75). The 
images are representative of three experiments.
Fig. 6. COX-2 inhibition and EGCG cell preincubation decrease MMP-9 levels. Cells were 
pretreated for 1 h with 25 M NS-398 or with 10 M EGCG and then with 27-OH (6 μM) or with 
HNE (5 μM) for 24 h. (A) MMP-9 gene expression was evaluated by real-time RT-PCR. The 
histograms represent mean values ± SD of three experiments, expressed as fold induction versus 
control and normalized to -actin. ***p<0.001, and *p<0.05 vs. control; §§§p<0.001 vs. 27-OH; 
#p<0.05 vs. HNE. (B) MMP-9 protein levels were analyzed using the ELISA method after 48 h of 
cell incubation with 27-OH or HNE. MMP-9 concentrations (pg/ml) were extrapolated from the 
standard curve. The histograms represent mean values ± SD of three experiments.  **p<0.01, and 
*p<0.05 vs. control; §§p<0.01 vs. 27-OH; ###p<0.001 vs. HNE.






